Immunotherapy in Glioblastoma: Genetic Insights and Innovations
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: 15 January 2026 | Viewed by 169
Special Issue Editor
Special Issue Information
Dear Colleagues,
Aim:
Glioblastoma (GBM), one of the most aggressive primary central nervous system (CNS) malignancies, exhibits several characteristics, including rapid growth, high invasiveness, inter- and intra-tumor heterogeneity, and high rates of recurrence. Traditional GBM treatment strategies are primarily surgery‐based. However, due to the highly invasive and diffuse nature of GBM, complete resection is often unachievable. Chemotherapeutic agents inhibit tumor growth by damaging tumor cell DNA, but many patients develop drug resistance, reducing therapeutic efficacy. Established in 2005, the STUPP protocol—which involves safe maximal resection followed by adjuvant chemoradiation—has not substantially changed prognosis, with a median survival of 15–20 months. In recent years, high‐throughput sequencing technologies and multi‐omics analyses have revealed intricate molecular features in GBM. Some of these techniques are as follows: genetic mutations (such as epidermal growth factor receptor (EGFR) amplification, TP53 mutations, and isocitrate dehydrogenase (IDH)1/2 mutations); epigenetic alterations (such as DNA methylation and histone modifications); the immunosuppressive nature of the tumor microenvironment; the regulatory roles of non‐coding (nc) RNAs (such as circular (circ)RNAs and micro (mi)RNAs); and the abnormal activation of multiple signaling pathways (such as the PI3K/AKT/mTOR and MAPK pathways). Recent research has increasingly focused on immunotherapies, such as chimeric antigen receptor T‐cell (CAR‐T) therapy and checkpoint inhibitors, aiming to enhance the body’s immune response to combat the tumor.
Scope:
Our scope involves enhancing recent advances in genetic insights and innovations in GBL treatment strategies.
Dr. Richard J. Tancredi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioblastoma
- treatment strategy
- genetic mutations
- immunotherapies
- checkpoint inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
